Patients with heart failure (HF) who contract SARS-CoV-2 infection are
at a higher risk of cardiovascular and non-cardiovascular morbidity and
mortality. Regardless of therapeutic attempts in COVID-19, vaccination
remains the most promising global approach at present for controlling
this disease. There are several concerns and misconceptions regarding
the clinical indications, optimal mode of delivery, safety and efficacy
of COVID-19 vaccines for patients with HF. This document provides
guidance to all healthcare professionals regarding the implementation of
a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination
is indicated in all patients with HF, including those who are
immunocompromised (e.g. after heart transplantation receiving
immunosuppressive therapy) and with frailty syndrome. It is preferable
to vaccinate against COVID-19 patients with HF in an optimal clinical
state, which would include clinical stability, adequate hydration and
nutrition, optimized treatment of HF and other comorbidities (including
iron deficiency), but corrective measures should not be allowed to delay
vaccination. Patients with HF who have been vaccinated against COVID-19
need to continue precautionary measures, including the use of facemasks,
hand hygiene and social distancing. Knowledge on strategies preventing
SARS-CoV-2 infection (including the COVID-19 vaccination) should be
included in the comprehensive educational programmes delivered to
patients with HF